TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme Deal
Tweet Send to a Friend
TD Cowen analyst Phil Nadeau reiterated a Buy rating and $120.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
